Sign in

You're signed outSign in or to get full access.

Yasmin Rahimi

Managing Director and Senior Research Analyst at Piper Sandler

Yasmeen Rahimi is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in biotechnology within the medical sector. She covers companies such as Pliant Therapeutics, Inventiva, and numerous others, with a performance track record including a 39-47% success rate across platforms like StockAnalysis (11.32% average return) and TipRanks (36% success rate), alongside predominantly overweight recommendations. Rahimi joined Piper Sandler in July 2020 after nearly three years as a senior research analyst and co-head of biotechnology equity research at ROTH Capital Partners, more than two years as an equity research associate at H.C. Wainwright and Guggenheim Partners, and earlier roles including medical researcher at Shire Pharmaceuticals. She holds a Ph.D. in biochemistry from Indiana University School of Medicine, a master’s degree in analytical chemistry from Purdue University, postdoctoral training at Yale University School of Medicine, and dual bachelor’s degrees in chemistry and German from Butler University.

Yasmin Rahimi's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership

Question · Q4 2025

Yasmin Rahimi (Piper Sandler) inquired about the specific key milestones and their contingencies for Prothena's partnered programs, PARAISO and CLEOPATTRA, expected in 2026 and 2027, given their primary completion dates are anticipated in 2029.

Answer

Gene Kinney, President and CEO, highlighted upcoming scientific presentations on CYTOPE technology and the TDP-43 CYTOPE program in 2026. He also pointed to the expected data from Bristol Myers Squibb's tau program (BMS-986446) Phase 2 trial in the first half of 2027, emphasizing its tau PET primary outcome. Tran Nguyen, Chief Strategy Officer and CFO, added that Prothena anticipates up to $105 million in clinical milestones from partners in 2026, tied to coramitug and PRX019 advancements, and confirmed plans for a share redemption program in 2026.

Ask follow-up questions

Fintool

Fintool can predict PROTHENA CORP PUBLIC LTD logo PRTA's earnings beat/miss a week before the call

Yasmin Rahimi's questions to Praxis Precision Medicines (PRAX) leadership

Question · Q4 2025

Yasmin Rahimi asked about Praxis Precision Medicines' pre-commercial activities for 2026 and the new data expected at the American Academy of Neurology (AAN) meeting.

Answer

CFO Tim Kelly detailed pre-commercial efforts including key hires, inventory build, and disease awareness campaigns for ulixacaltamide. President and CEO Marcio Souza highlighted 15 presentations at AAN, focusing on oral presentations of Essential3 program clinical data and expanding understanding of the MADRS-11 endpoint for neurologists.

Ask follow-up questions

Fintool

Fintool can predict Praxis Precision Medicines logo PRAX's earnings beat/miss a week before the call